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Precis:  Early hospital participation in the MSSP ACO program was not associated with 
greater reductions in adverse perioperative outcomes for patients undergoing a major 
cancer surgery compared to control hospitals.  The longitudinal improvements in 
perioperative outcomes identified during the study interval may reflect the impact of 
concurrent policies more directly applicable to surgical patients.   
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Background: Accountable Care Organizations (ACOs) were established to improve 
care and outcomes for beneficiaries requiring highly coordinated, complex care. Our 
objective was to evaluate the association between hospital ACO participation and 
outcomes of major surgical oncology procedures. 
Methods:  We performed a retrospective cohort study of Medicare beneficiaries >65 
years old undergoing a major surgical resection for colorectal, bladder, esophageal, 
kidney, liver, ovarian, pancreatic, lung or prostate cancer from 2011 through 2013. We 
implemented a difference-in-differences analysis comparing the post-implementation 
period (January 2013 through December 2013) to the baseline period (January 2011 
through December 2012), to assess the impact of hospital ACO participation on 30-day 
mortality, complications, readmissions and length of stay. 
Results:  Among 384,519 patients undergoing major cancer surgery at 106 ACO 
hospitals and 2,561 control hospitals, we identified a 30-day mortality rate of 3.4%, 
readmission rate of 12.5%, complication rate of 43.8% and prolonged LOS rate of 
10.0% in control hospitals, with similar rates in ACO hospitals.  We noted secular 
trends, with reductions in perioperative adverse events in control hospitals between the 
baseline and post-implementation periods: mortality (0.1% percentage point reduction, 
p=0.19), readmissions (0.4%, p=0.001), complications (1.0%, p<0.001) and prolonged 
LOS (1.1%, p<0.001). After accounting for these secular trends, we identified no 
significant effect of hospital participation in an ACO on the frequency of perioperative 
outcomes (difference-in-differences estimator p-values 0.24-0.72).   
Conclusions: Early hospital participation in the MSSP ACO program was not 
associated with greater reductions in adverse perioperative outcomes for patients 
undergoing major cancer surgery compared to control hospitals.  
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Accountable care organizations (ACOs) are a signature reform of the Affordable 
Care Act intended to create highly integrated delivery systems that improve population 
health and reduce costs through increased accountability and care coordination.1 
Architects of ACO policies envisioned that physicians and other healthcare workers 
would come together as multidisciplinary teams to coordinate and optimize care for 
complex and expensive patients.2 Precursors to ACOs, such as the Physician Group 
Practice (PGP) demonstration, provided proof-of-principle that similar models can 
achieve gains in the quality and cost of care provided to medical patients with multiple 
comorbidities.3 
 Despite this evidence from primary care, it remains unknown whether ACO 
participation will have similar benefits for delivery of more technically complex, 
specialist-oriented services. Given its organization around multidisciplinary provider 
teams, cancer care represents an important clinical domain for evaluating this question.  
It is possible, for instance, that hospital ACO participation serves as a catalyst for 
developing integrated teams that collaborate to improve care processes and outcomes 
for patients undergoing cancer treatment.   In this scenario, one group that may derive 
early benefits from the ACO model is patients undergoing major cancer surgery. For 
these patients with cancer, the heightened focus on quality and care coordination that 
accompanies ACO participation might translate quickly into improved perioperative 
outcomes.  
 In this context, we used national Medicare data to examine the early impact of 
hospital ACO participation on outcomes with major cancer surgery. We specifically 
performed a difference-in-differences analysis to examine the association between 
hospital participation in a Medicare Shared Savings Program (MSSP) ACO and length 
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of stay, 30-day mortality, major complications, and readmissions after major oncological 
surgery.  We hypothesize that benefits from ACO implementation would most likely 
occur in the form of decreased rates of readmission and complications and shorter 
length of stay that would result from improvements in processes of care that are at the 




 We used three datasets to perform these analyses.  First, we used the Medicare 
Shared Savings Program (MSSP) ACO Provider-level Research Identifiable File 
(available from the Centers for Medicare and Medicaid Services (CMS)) to identify 
hospitals that formally participated in the MSSP during the first performance period from 
April 2012 through December 2013.  Next, we used the American Hospital Association 
Annual Survey to evaluate hospital characteristics including region, number of beds, 
hospital profit status, hospital teaching status, number of operating rooms and electronic 
health record use.  Finally, we used the 100% Medicare Provider Analysis and Review 
(MEDPAR) file from 2011 through 2013 to identify patient cohorts, demographic and 
clinical information, and the occurrence of our outcomes of interest.   
 
Identification of ACO participating and nonparticipating hospitals 
 Using the MSSP ACO Provider-level dataset, we identified acute care and critical 
access hospitals that enrolled in an MSSP ACO during the first performance period.  
These hospitals are referred to as ACO hospitals throughout the manuscript; 
conversely, hospitals that were not formal MSSP ACO participants are referred to as 
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control hospitals.  Hospitals with fewer than 10 oncologic procedures overall performed 
during the period of interest were excluded. 
 
Identification of study population 
 We used diagnosis and procedures codes from the International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) to identify patients aged 66 
to 99 years that underwent major cancer surgery during the study interval for the 
following nine solid organ cancers:  colorectal, bladder, esophageal, kidney, liver, 
ovarian, pancreatic, lung or prostate cancer (Supplemental Material 1).  We included 
only those patients who had a procedure and were discharged between January 1, 
2011 and November 30, 2013 to ensure adequate follow-up for ascertainment of post-
operative outcomes.  We excluded patients who had two or more different oncologic 
procedures on the same day or ≤180 days apart. 
 
Outcome measures 
 We measured four post-operative outcomes: mortality, complications, prolonged 
length of stay (LOS) and readmissions.  Mortality, complications, and readmissions 
were identified within 30 days of the index cancer operation.  Complications were 
identified using established methods based on the Complication Screening Program.4–6 
Using this method, we identified events including infectious, bleeding, pulmonary, renal, 
cardiac, neurologic, gastrointestinal and other complications occurring during the index 
hospitalization or within 30 days of surgery.  Prolonged LOS was defined as a LOS that 
exceeded 90th percentile on a procedure specific basis. 
 
Statistical analysis  
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We used Student’s t-test and chi-square tests where appropriate to compare 
characteristics of hospitals that participated in an MSSP ACO versus those that did not.  
We also compared demographic characteristics for patients treated in MSSP ACO 
hospitals versus control hospitals.   
Next, we implemented a difference-in-differences analysis to evaluate the 
association between hospital participation in an MSSP ACO and changes in 
perioperative outcomes over time compared to control hospitals.3,7 To do this, we first 
specified whether each hospital in our sample was an ACO hospital versus a control 
hospital. We then specified a time variable that reflects the period before and after 
MSSP ACO policy implementation.  ACO hospital cases were included in the post-
implementation time period starting on the specific date of ACO enrollment for that 
hospital (April 1, 2012, July 1, 2012 or January 1, 2013).  Control hospital cases were 
included in the post-implementation era beginning on January 1, 2013 because the 
majority of ACO participating hospitals entered their contracts on this date. We refer to 
the time period before ACO policy implementation as baseline, and the time period after 
as post-implementation. 
We initially fit logistic regression models for each outcome across all cancer 
procedures combined. For each model, we included an interaction term between 
hospital ACO participation and time to evaluate the effect of the ACO policy. The 
interaction term allows the predicted outcome to differ between patients treated in ACO 
hospitals and non-ACO hospitals in both the pre- and post-periods.  The difference-in-
differences of the predicted outcomes is then the causal effect of ACO on each 
outcome, controlling for trends in the control group.8–10 We adjusted our regression 
models for the type of surgery (e.g., colectomy, prostatectomy); patient characteristics 
including age, gender, race, and comorbidities (using the Elixhauser method); and 
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hospital characteristics including, geographic region, profit status, teaching status, rural 
versus urban location, and cancer procedure volume.11 For each of these models, we 
implemented robust standard errors to account for clustering of patient outcomes within 
hospitals.   
In addition to the overall models, we also fit similar cancer procedure-specific 
models for each of the perioperative outcomes.  Finally, we performed three sensitivity 
analyses.  First, we evaluated the effect of setting the post-implementation time point for 
control hospital cases at July 1, 2012, rather than January 1, 2013.  Second, we 
adjusted our overall model for three covariates that may act as markers of integration 
within a hospital delivery system including electronic health record use, familiarity with 
managed care contracts (Medicare Advantage penetration) and participation in a 
hospital network.  Last, we evaluated outcomes only in hospital referral regions 
containing both an ACO hospital and a control hospital. All statistical analyses were 
performed using Stata version 14 (StataCorp LP, College Station, Texas); p-values 
<0.05 were considered statistically significant.  The University of Michigan Institutional 
Review Board deemed this study exempt from review. 
 
Results 
 We identified more than 380,000 patients that underwent major cancer surgery at 
106 ACO hospitals and 2,561 control hospitals from 2011 through 2013.  ACO hospitals 
were concentrated in the Northeast and Midwest regions, were more often non-profit, 
urban, and teaching hospitals, and had a greater number of hospital beds compared to 
control hospitals (Table 1).  
We observed small but statistically significant differences in the populations 
served by these two hospital groups. For instance, patients treated at ACO hospitals 
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were more often white, and had a higher prevalence of measured comorbid conditions 
(Table 2). Although statistically significant, differences in the mix of oncological 
procedures between ACO hospitals and control hospitals were small, with ACO 
hospitals performing more prostate and ovarian cancer surgeries, and control hospitals 
performing more bladder, lung and liver cancer procedures.   
In the baseline study interval, unadjusted rates of 30-day mortality (3.3% vs. 
3.4%, p=0.54), 30-day readmission (12.5% vs. 12.4%, p=0.69), complications (43.6% 
vs. 43.4% p=0.65), and prolonged LOS (10.1% vs. 10.2% p=0.56) were similar between 
ACO hospitals and control hospitals.  The adjusted rates for these events were also 
comparable at baseline between ACO participants and control hospitals (Table 3). 
We found ACO hospitals did not improve at a significantly accelerated rate 
compared to control hospitals.  We noted secular trends, with reductions in 
perioperative adverse events in control hospitals between the baseline and post-
implementation periods: mortality (0.1% percentage point reduction, p=0.19), 
readmissions (0.4%, p=0.001), complications (1.0%, p<0.001) and prolonged LOS 
(1.1%, p<0.001). After accounting for these secular trends, we identified no significant 
effect of hospital participation in an ACO on the frequency of any perioperative 
outcomes (p-values for difference-in-differences estimator 0.24-0.72, Figure 1).  
 Finally, when we examined the association between hospital ACO participation 
and perioperative outcomes for individual cancers we noted similar patterns, with no 
greater improvements in perioperative outcomes for ACO hospitals (Supplemental 
Material 2).  Table 4 presents site-specific outcomes for several cancers comparing 
post-implementation outcomes to baseline.  We noted no substantive changes in our 
results in sensitivity analyses where the post-implementation date for control hospitals 
was changed from January 1, 2013 to July 1, 2012, when controlling for additional 
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measures of health system integration or when limiting our analyses to only markets 
containing both an ACO hospital and a control hospital. 
 
Discussion 
Our study has two principal findings. First, early hospital participation in the 
MSSP ACO program did not accelerate improvements in several adverse events (i.e., 
30-day mortality, readmissions, major complications, and prolonged LOS) after major 
cancer surgery compared to control hospitals.  Second, with the exception of mortality, 
rates of these adverse perioperative outcomes are improving across hospitals over 
time, with 0.1-1.6% percentage point reductions in the frequency of observed adverse 
events from baseline to post-implementation of ACO policies.  
Our findings showing no greater benefits with mortality or length of stay for 
patients undergoing cancer surgery in ACO hospitals is consistent with prior work 
evaluating outcomes for beneficiaries with cancer during the Physician Group Practice 
(PGP) demonstration project.12 Namely, cancer patients treated at facilities participating 
in PGP had rates of in-hospital mortality that were equivalent to those for a similar 
patient cohort treated in non-PGP hospitals. Likewise, there was no effect of PGP 
participation on the number of days that patients with cancer spent in the hospital. 
Although not attributable to ACO participation, there are several potential 
explanations for the observed decline in readmissions and complications over the study 
interval. For instance, work by others has demonstrated similar trends associated with 
concurrent CMS pay-for-performance initiatives including the Hospital Readmission 
Reduction Program (HRRP), Value Based Purchasing (VBP) program, and the Hospital-
Acquired Conditions Reduction program (HAC).13–16 While not directed specifically at 
patients undergoing cancer surgery, processes developed to reduce readmissions in 
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response to the HRRP, particularly those directed at surgical admissions, may well have 
spillover benefits for other surgical patients.  Likewise, improvements in care processes 
and patient safety in response to VBP and HAC metrics may have the collateral benefit 
of shortening length of stay and reducing readmissions for patients undergoing major 
cancer surgery.17 Accordingly, the observed longitudinal improvements in cancer 
surgical outcomes are likely related to a combination of initiatives implemented during 
the same time period as the MSSP ACO program.   
 Our study has several limitations.  First, most ACO quality metrics are not 
specifically focused on improving cancer care. Accordingly, further improvements in 
care delivery may require policies directed at cancer care specifically, rather than more 
general initiatives like ACOs.   However, while these specific surgical outcome 
measures may not map directly to MSSP ACO quality measures, improvements in 
perioperative outcomes should translate into lower costs of care, which is highly 
relevant for ACO performance.  It is also conceivable that incremental improvements in 
cancer care may be more difficult to achieve through the ACO model since there has 
long been a focus on care coordination and quality measurement in this patient 
population.  Moreover, organizational change may require more than one or two years 
and effects derived from ACO policies may become stronger over time and as more 
organizations form.  Second, we did not evaluate for improvements in cancer screening, 
surveillance and end of life care. In many ways, these domains of cancer care may be 
more responsive to the ACO model than surgical outcomes, from both a cost and 
quality perspective.  As a result, future evaluations of cancer care and outcomes in 
ACOs are needed to define the impact of this model on these distinct phases of cancer 
care.18 Third, our study assumes there were no inherent differences between control 
hospitals and hospitals that ultimately joined an ACO.  While, ACO hospitals and control 
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hospitals are not identical, they have similar patient populations and had equivalent 
outcome rates at baseline.  Additionally, our study design assumes that outcome trends 
during the baseline period were similar among ACO hospitals and control hospitals.  As 
more data becomes available, evaluating time trends across the baseline and post-
implementation periods will be important to consider.  Finally, hospital affiliation with an 
ACO represents one mechanism for ACO participation.  Additionally, physicians can 
align with an ACO independent of hospital participation.  While our study does not 
examine the role of physician ACO participation, control hospitals with a large number 
of ACO participating physicians may be influenced by ACO policies.    
 These limitations notwithstanding our findings have important implications for 
ACO leadership and policymakers.  For ACO leadership, simply committing to the 
framework, measures, and payment changes that come with ACO participation will not 
necessarily translate into short-term improvements in perioperative outcomes for cancer 
patients.  Nonetheless, our findings showing improvements in care regardless of 
hospital ACO status suggests that ACOs may benefit from other ongoing quality 
improvement programs that are impacting care at hospitals nationwide. For instance, 
reducing surgical site infections after colectomy will positively impact hospital 
performance with both the VBP and HAC programs, while also reducing costs for the 
ACO.   
For policymakers, our findings suggest that, at least in this early period, 
innovative policies based on ACO principles (e.g., primary care focus) may have limited 
impact on inpatient surgical care.  Programs directed specifically at improving surgical 
and cancer specific outcomes—such as surgical quality improvement collaboratives or 
initiatives through oncology groups such as the American Society of Clinical Oncology’s 
Institute for Quality—may offer alternative and more direct ways for physicians, patients 
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and health systems to partner to improve outcomes and reduce costs with major cancer 
surgery.19,20 
Although longer follow-up is needed, early hospital participation in the MSSP 
ACO program was not associated with greater reductions in adverse perioperative 
outcomes for patients undergoing a major cancer surgery compared to nonparticipating 
hospitals.  The longitudinal improvements in perioperative outcomes identified during 
the study interval may reflect the impact of concurrent policies more directly applicable 
to surgical patients.  Moving forward, studies that inform the impact of ACOs at other 
points in the cancer care continuum (e.g., early detection, end-of-life care) will further 
clarify the relevance and impact of this model in oncology. 
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Figure 1.  Change in rates of perioperative outcomes after ACO implementation.   
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Annual oncologic surgical volume, median (IQR) 31.3 (10.7-90.3) 23.3 (9-58.7) 0.06 
Geographic region (%) <0.001 
Northeast 25.5 17.1 
Midwest 48.1 25.0 
South 23.6 37.9 
West 2.8 20.2 
Number of beds 0.02 
<200 42.5 52.5 
200-349 24.5 27.0 
350-499 19.8 11.3 
≥500 13.2 9.3 
Hospital profit status (%) <0.001 
For-profit 4.7 17.6 
Non-profit 86.8 69.0 
Public 8.5 13.4 
Other characteristics 
Teaching hospital (%) 48.1 34.1 0.002 
Urban location (%) 84.0 72.4 0.01 
Number of operating rooms, median (IQR) 11 (5-19) 9 (5-14) 0.09 
Electronic health record implemented (%) 95.7 98.1 0.24 
Medicare Advantage penetration (%)* 25.9 25.7 0.90 
  Network participant 51.4% 40.7% 0.03 
*Medicare Advantage penetration is reported at the county level 
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for ACO versus 
control hospitals 
p-value 
Age 74.44 74.49 74.15 74.39 -0.20 0.002 
Female (%) 42.27 41.87 42.19 42.11 -0.32 0.42 
Race (%) <0.001 
White 87.63 86.58 87.25 86.04 0.16 
Black 8.74 8.17 8.69 8.14 -0.02 
 Other 
3.63 5.25 4.06 5.83 -0.15  
Cancer Surgery (%) 
Bladder 4.09 4.27 3.86 4.45 -0.41 0.02 
Prostate 18.37 17.40 17.21 16.21 0.03 0.004 
Esophageal 0.98 1.12 1.12 1.20 0.06 0.19 
Pancreas 2.95 3.04 3.28 3.21 0.16 0.93 
Lung 17.19 17.55 17.69 18.21 -0.16 0.24 
Liver 0.74 1.04 1.03 1.16 0.17 0.01 
Kidney 11.82 12.11 12.23 12.69 -0.17 0.25 
Colorectal 39.03 39.00 38.35 38.26 0.06 0.86 
Ovarian 4.83 4.47 5.22 4.60 0.26 0.001 
Comorbid diseases (%) 
Congestive heart failure 8.80 7.74 8.36 7.39 -0.09 <0.001 
Valvular disease 5.99 5.77 5.55 5.89 -0.56 0.91 
Pulmonary hypertension 2.37 1.94 2.42 1.96 0.04 <0.001 
Peripheral vascular disease 7.40 6.89 6.74 7.25 -1.02 0.62 
Paralysis 1.10 0.93 0.87 0.90 -0.20 0.33 
Other neurological disorders 3.63 3.17 3.10 3.24 -0.59 0.14 
Chronic pulmonary disease 24.81 22.92 23.90 22.92 -0.90 <0.001 
Diabetes w/o complication 23.54 22.45 24.42 22.77 0.56 <0.001 
Diabetes with complication 2.50 2.72 3.32 2.94 0.60 0.43 
Hypothyroidism 11.48 12.21 12.65 13.02 0.35 0.08 
Renal failure 0.80 0.84 0.83 0.87 0.00 0.56 
Liver disease 0.74 1.04 1.03 1.16 0.17 0.01 
Lymphoma 0.67 0.74 0.70 0.75 0.03 0.38 
Metastatic cancer 18.14 19.06 18.98 18.48 1.43 0.23 
Solid tumor without mets 
(other than primary) 9.43 9.53 9.76 9.65 0.20 0.94 
Rhematologic disorder 2.27 2.27 2.62 2.46 0.16 0.34 
Coagulopathy 3.73 3.48 4.26 3.67 0.34 0.001 
Obese 9.67 8.91 10.67 10.33 -0.42 <0.001 
Weight loss 9.23 8.72 9.56 8.69 0.37 0.001 
Electrolyte disorders 22.54 21.86 23.44 22.18 0.58 0.001 
Blood loss anemia 3.88 3.51 3.56 3.19 0.01 0.02 
Deficiency anemias 21.45 20.92 21.01 20.12 0.36 0.06 
Psychoses 1.96 1.87 1.88 1.96 -0.17 0.79 
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Depression 7.95 7.43 8.69 7.95 0.21 <0.001 
  Hypertension 66.17 65.29   66.97 65.65 0.44 0.001 
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Table 3.  Adjusted rates of adverse perioperative outcomes for patients undergoing cancer 
surgery at hospitals before and after ACO policy implementation. 
Control hospitals ACO hospitals 
Baseline Post-implementation Baseline Post-implementation 
30-day Mortality 3.4% 3.3% 3.4% 3.2% 
Readmissions 12.5% 12.1%* 12.6% 12.0% 
Complications 43.8% 42.7%* 44.0% 42.5% 
Prolonged LOS 10.0% 8.9%* 10.0% 8.4% 
Adjusted for surgery type, age, gender, race, region, bed size, hospital profit status, teaching 
status, rural/urban location, cancer procedure volume and comorbidities  
*Change from baseline (p≤0.001) 
 
Legend:  Statistically significant decline in readmissions, complications and prolonged 
LOS for patients undergoing a major cancer surgery at control hospitals with parallel 
trends in perioperative outcomes at ACO hospitals. 
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Table 4.  Relative risk of adverse perioperative outcomes in control hospitals during the 
post-implementation versus baseline time periods (*p<0.05). 
 
Mortality Readmissions Complications Prolonged LOS 
Prostate 0.84 (0.57-1.24) 1.03 (0.95-1.11) 0.97 (0.93-1.02) 0.89 (0.83-0.94)* 
Bladder 1.14 (0.93-1.41) 1.01 (0.95-1.07) 0.98 (0.96-1.00) 0.89 (0.79-1.00) 
Esophagus 0.83 (0.55-1.24) 1.06 (0.90-1.24) 0.92 (0.86-0.99)* 0.73 (0.55-0.97)* 
Pancreas 0.95 (0.75-1.20) 1.01 (0.93-1.10) 0.95 (0.91-0.99)* 0.86 (0.74-0.99)* 
Lung 0.98 (0.89-1.07) 0.91 (0.87-0.95)* 0.92 (0.90-0.95)* 0.88 (0.84-0.92)* 
Liver 0.86 (0.59-1.26) 0.92 (0.76-1.11) 0.96 (0.88-1.04) 0.74 (0.60-0.92)* 
Kidney 1.11 (0.98-1.30) 0.97 (0.91-1.03) 0.99 (0.97-1.01) 0.92 (0.87-0.98)* 
Colorectal 1.00 (0.95-1.04) 0.96 (0.94-0.99)* 0.99 (0.98-1.00) 0.89 (0.86-0.92)* 
Ovary 0.71 (0.59-0.86) 0.98 (0.90-1.06) 0.98 (0.95-1.01) 0.92 (0.84-1.02) 
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Supplemental Material 1.  Cohort selection. 
 
Cancer type Diagnosis codes (ICD-9) Procedure codes (ICD-9) 
Prostate 185 603 604 605 6061 6062 6069 
Bladder 188 1880 1881 1882 1883 
1884 1885 1886 1887 1888 
1889 
576 577 5771 5779  
Esophagus 150 1500 1501 1502 1503 
1504 1505 1508 1509 
424 4240 4241 4242   4399 
Pancreas 157 1570 1571 1572 1573 
1574 1575 1576 1577 1578 
1579 
5252 5251 5253 525 526 527 5259 5222 
Lung 162 1620 1621 1622 1623 
1624 1625 1626 1627 1628 
1629 
322 3220 329 3229 3230 3239 324 3241 3249 
3250 3529 325 
Liver 155 1550 1551 1552 5022 503 504 5059 502 5029 
Kidney 189 1890 18900 18901 1898 
1891 23691 
554 5551 5552 5554 5534 5532 555 
Colorectal 1530 1531 1532 1533 1534 
1535 1536 1537 1538 1539 
1540 1541 
457 4571 4572 4573 4574 4575 4576 4579 
4849 4581 4582 4583 458 4861 4865 4869 
4862 4863 4864 4850 4851 4852 4859 4840 
4841 4842 4843 485 486 484 1732 1733 1734 
1735 1736 1739 
Ovarian 1830 652 6531 6539 6551 6552 6553 6554 6541 
6549 6561 6562 6563 6564 664 665 654 656 
688 683 6831 6839 684 6841 6849 685 6851 
6859 686 6861 6869 687 6871 6879 689 541 
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Supplemental Material 2.  Percentage point change in adverse perioperative outcomes 
attributable to ACO policy (difference-in-differences estimator) by cancer type (*p<0.05) 
 
  Mortality Readmissions Complications Prolonged LOS 
Prostate 0.01 (-0.21-0.22) -1.44 (-2.93-0.08) 0.43 (-1.75-2.61) 0.38 (-0.94-1.63) 
Bladder -1.59 (-4.75-1.50) -3.51 (-9.61-2.48) -4.15 (-10.05-2.31) -0.03 (-4.23-3.96) 
Esophagus 2.19 (-2.13-7.67) -8.67 (-21.88-2.52) -10.19 (-26.33-5.30) 2.73 (-8.12-13.63) 
Pancreas 2.39 (-0.68-5.43) 3.70 (-2.10-9.23) -3.92 (-12.43-4.39) -0.28 (-3.41-3.15) 
Lung -0.16 (-1.21-0.87) 1.21 (-1.14-3.57) -0.22 (-3.63-3.09) 0.40 (-1.61-2.31) 
Liver -2.06 (-4.37-1.10) 3.80 (-10.98-18.78) -13.3 (-25.69- -3.24)* 0.05 (-19.12-19.30) 
Kidney -0.19 (-1.28-0.90) 0.98 (-1.20-3.16) -2.17 (-6.07-1.76) -0.56 (-3.08-1.95) 
Colorectal -0.08 (-1.08-0.92) -0.32 (-1.97-1.30) 0.45 (-1.93-2.84) -0.90 (-2.30-0.49) 
Ovary 0.25 (-2.30-2.76) 0.87 (-4.18-6.53) -1.63 (-8.83-5.56) -0.33 (-3.35-2.74) 
Legend: Negative values indicate further decline in adverse events attributable to ACO policies 
(benefit beyond change seen in control hospitals). 
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